UnitedHealth shareholders push company to report on impact of claims denials

A contingent of UnitedHealth Group shareholders has requested that the company investigate and develop a report on the impact of "practices that limit or delay access to healthcare." 

According to a report from Reuters, the proposal is slated to be voted on during the company’s next annual shareholder meeting. A spokesperson told the outlet that the company will respond once the concerned shareholders file the proper documents to add this item to the agenda for the 2025 meeting, which has yet to be scheduled.

The group that filed the motion intends to raise the issue for discussion regardless of how shareholders vote. The Sisters of the Holy Names of Jesus and Mary of Quebec is leading the charge alongside Trillium Asset Management.

The move has earned support from Center for Health & Democracy, a public health advocacy group, as well as the Interfaith Center on Corporate Responsibility.

According to the report, the groups are requesting an analysis of the prior authorization process, which is used to determine when and how care delivery is covered by insurance for patients enrolled in Medicare Advantage and other health plans.

The issue of delayed and denied care has become a focal point of discussion in the weeks following the murder of UnitedHealthcare CEO Brian Thompson, who was shot and killed in New York City by a vigilante. A Maryland man, Luigi Mangione, has been charged with the crime and remains behind bars, awaiting trial.

Read the full article from Reuters at the link below.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”